Abdel-wahab, Omar

Publications

Sort by

Co-Author Network

selected publications

A new SAGA for AML: targeting SGF29 in AML. Blood. 2024 Editorial Article GET IT
SWI/SNF regulation of germinal center fate and lymphomagenesis. Cancer cell. 2024 Academic Article GET IT
Targeting the cBAF complex in T-ALL. Blood. 2024 Editorial Article GET IT
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.). 2024 Academic Article GET IT
A microglia clonal inflammatory disorder in Alzheimer's Disease. 2024 GET IT
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Science translational medicine. 2024 Academic Article GET IT
Covalent Targeting of Splicing in T Cells. 2023 GET IT
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Nature communications. 2023 Academic Article GET IT
SRSF2 plays an unexpected role as reader of m⁵C on mRNA, linking epitranscriptomics to cancer. Molecular cell. 2023 Academic Article GET IT
Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models. The Journal of clinical investigation. 2023 Academic Article GET IT
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature cancer. 2023 Academic Article GET IT
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nature communications. 2023 Academic Article GET IT
Histiocytic neoplasm subtypes differ in their MAP2K1 mutations. Blood advances. 2023 Academic Article GET IT
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. Blood advances. 2023 Academic Article GET IT
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nature cancer. 2023 Academic Article GET IT
Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells. The New England journal of medicine. 2023 Letter GET IT
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood advances. 2023 Academic Article GET IT
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 2023 Academic Article GET IT
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia. NEJM evidence. 2023 Academic Article GET IT
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood advances. 2023 Academic Article GET IT
Times cited: 5
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood reviews. 2023 Review GET IT
Genome-wide association study identifies the first germline genetic variant associated with Erdheim Chester disease. Arthritis & rheumatology (Hoboken, N.J.). 2023 Academic Article GET IT
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell stem cell. 2023 Academic Article GET IT
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression. Blood advances. 2023 Academic Article GET IT
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Comment GET IT
Times cited: 2
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. British journal of haematology. 2023 Academic Article GET IT
Times cited: 1
CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition. Leukemia. 2023 Letter GET IT
Immune Escape after Allogeneic Hematopoietic Cell Transplantation in Pediatric Acute Myeloid Leukemia. Blood advances. 2023 Academic Article GET IT
RBM33: A new regulator of N-6-methyladenosine (m⁶A) methylation. Molecular cell. 2023 Academic Article GET IT
Overlaid Transcriptional and Proteome Analyses Identify Mitotic Kinesins as Important Targets of Arylsulfonamide-Mediated RBM39 Degradation. Molecular cancer research : MCR. 2023 Academic Article GET IT
Overlaid transcriptome and proteome analyses identify mitotic kinesins as important targets of arylsulfonamide-mediated RBM39 degradation. Molecular cancer research : MCR. 2023 Academic Article GET IT
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023 Academic Article GET IT
Times cited: 1
Proteomic discovery of chemical probes that perturb protein complexes in human cells. Molecular cell. 2023 Academic Article GET IT
Times cited: 16
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood reviews. 2023 Review GET IT
Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Editorial Article GET IT
Times cited: 2
Acquired BAX mutations in AML. Blood. 2023 Editorial Article GET IT
New readers and writers of RNA modifications unique to leukemia stem cells. Cell stem cell. 2023 Comment GET IT
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022 Academic Article GET IT
Times cited: 6
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer cell. 2022 Academic Article GET IT
Times cited: 14
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS. Blood advances. 2022 Academic Article GET IT
Times cited: 4
Harnessing introns to monitor gene expression. Nature cell biology. 2022 Comment GET IT
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American journal of hematology. 2022 Academic Article GET IT
Times cited: 3
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leukemia research. 2022 Academic Article GET IT
Times cited: 1
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 Letter GET IT
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood advances. 2022 Academic Article GET IT
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. Cancer discovery. 2022 Academic Article GET IT
Times cited: 10
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer discovery. 2022 Academic Article GET IT
Times cited: 24
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature immunology. 2022 Academic Article GET IT
Times cited: 12
Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nature genetics. 2022 Academic Article GET IT
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Blood. 2022 Academic Article GET IT
Times cited: 9
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI insight. 2022 Academic Article GET IT
Times cited: 13
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine. 2022 Academic Article GET IT
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer research. 2022 Academic Article GET IT
Times cited: 5
Dysregulation and therapeutic targeting of RNA splicing in cancer. Nature cancer. 2022 Review GET IT
Times cited: 42
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular cell. 2022 Academic Article GET IT
Times cited: 9
Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood. 2022 Academic Article GET IT
Times cited: 32
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nature biotechnology. 2022 Academic Article GET IT
Times cited: 22
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies. Blood cancer discovery. 2022 Editorial Article GET IT
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes & development. 2022 Review GET IT
Times cited: 16
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. The New England journal of medicine. 2022 Academic Article GET IT
Times cited: 89
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Academic Article GET IT
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology. 2021 Academic Article GET IT
Times cited: 52
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia. 2021 Academic Article GET IT
Times cited: 3
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature biotechnology. 2021 Academic Article GET IT
Times cited: 3
Structural basis of cytokine-mediated activation of ALK family receptors. Nature. 2021 Academic Article GET IT
Times cited: 16
Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer discovery. 2021 Academic Article GET IT
Times cited: 44
Promoting spliceosome assembly for therapeutic intent. Trends in pharmacological sciences. 2021 Academic Article GET IT
Times cited: 3
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood cancer journal. 2021 Academic Article GET IT
Times cited: 27
Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro-oncology. 2021 Review GET IT
Times cited: 32
mRNA Export as a Novel Cancer-Specific Dependency. Cancer discovery. 2021 Comment GET IT
Splicing factor mutations in hematologic malignancies. Blood. 2021 Review GET IT
Times cited: 38
Splicing regulation in hematopoiesis. Current opinion in hematology. 2021 Review GET IT
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021 Academic Article GET IT
Times cited: 114
AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia. Cancer discovery. 2021 Academic Article GET IT
Times cited: 23
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular cell. 2021 Academic Article GET IT
Times cited: 57
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease. Trends in molecular medicine. 2021 Review GET IT
Times cited: 27
MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor perspectives in medicine. 2021 Review GET IT
Times cited: 15
Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL. Blood. 2021 Academic Article GET IT
Histiocytosis. Lancet (London, England). 2021 Review GET IT
Times cited: 54
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature genetics. 2021 Academic Article GET IT
Times cited: 56
Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature communications. 2021 Academic Article GET IT
Times cited: 48
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood advances. 2021 Academic Article GET IT
Times cited: 100
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet (London, England). 2021 Academic Article GET IT
Times cited: 203
The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 13
High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood. 2021 Academic Article GET IT
Times cited: 29
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. Leukemia. 2021 Academic Article GET IT
Times cited: 15
U2af1 is required for survival and function of hematopoietic stem/progenitor cells. Leukemia. 2021 Academic Article GET IT
Times cited: 20
Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis. The Journal of clinical investigation. 2021 Academic Article GET IT
Times cited: 19
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 26
The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. Cancers. 2020 Academic Article GET IT
Times cited: 4
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood. 2020 Academic Article GET IT
Times cited: 39
Oncogenic splicing regulated by phase separation. Nature cell biology. 2020 Comment GET IT
Times cited: 1
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. The Lancet. Haematology. 2020 Academic Article GET IT
Times cited: 12
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro-oncology. 2020 Academic Article GET IT
Times cited: 23
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer cell. 2020 Academic Article GET IT
Times cited: 92
ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase. Cell metabolism. 2020 Academic Article GET IT
Times cited: 37
Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood. 2020 Academic Article GET IT
Times cited: 13
DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nature genetics. 2020 Academic Article GET IT
Times cited: 129
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer discovery. 2020 Academic Article GET IT
Times cited: 58
ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. Cell reports. 2020 Academic Article GET IT
Times cited: 16
Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. Neuro-oncology advances. 2020 Academic Article GET IT
Times cited: 11
Genetic basis for iMCD-TAFRO. 2020 GET IT
Times cited: 12
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 136
Recurrent SRSF2 mutations in MDS affect both splicing and NMD. Genes & development. 2020 Academic Article GET IT
Times cited: 37
SnapShot: Splicing Alterations in Cancer. Cell. 2020 Academic Article GET IT
Times cited: 50
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature medicine. 2019 Academic Article GET IT
Times cited: 114
PTEN isoforms with dual and opposing function. Nature cell biology. 2019 Comment GET IT
Times cited: 6
Altered RNA Processing in Cancer Pathogenesis and Therapy. Cancer discovery. 2019 Review GET IT
Times cited: 85
Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019 Academic Article GET IT
Times cited: 132
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019 Academic Article GET IT
Times cited: 131
Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. Science translational medicine. 2019 Academic Article GET IT
Times cited: 10
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer cell. 2019 Academic Article GET IT
Times cited: 159
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. Cancer discovery. 2019 Academic Article GET IT
Times cited: 53
Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019 Academic Article GET IT
Times cited: 154
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2019 Article GET IT
Times cited: 30
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 34
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature communications. 2019 Academic Article GET IT
Times cited: 54
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular cancer therapeutics. 2019 Academic Article GET IT
Times cited: 24
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood advances. 2019 Academic Article GET IT
Times cited: 17
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Academic Article GET IT
Times cited: 203
BRAF in the cross-hairs. Expert review of hematology. 2019 Review GET IT
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer cell. 2019 Academic Article GET IT
Times cited: 187
Activating p53 and Inhibiting Superenhancers to Cure Leukemia. Trends in pharmacological sciences. 2018 Comment GET IT
Times cited: 5
Aberrant RNA Splicing in Cancer. Annual review of cancer biology. 2018 Academic Article GET IT
Times cited: 54
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica. 2018 Article GET IT
Times cited: 4
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer research. 2018 Academic Article GET IT
Times cited: 15
ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching. Journal of proteome research. 2018 Academic Article GET IT
Times cited: 21
Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 56
Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature. 2018 Academic Article GET IT
Times cited: 139
Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens. Cancer cell. 2018 Comment GET IT
Times cited: 35
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer cell. 2018 Academic Article GET IT
Times cited: 140
Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological oncology. 2018 Review GET IT
Times cited: 2
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2018 Academic Article GET IT
Times cited: 42
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene. 2018 Academic Article GET IT
Times cited: 85
Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem cell reports. 2018 Academic Article GET IT
Times cited: 40
Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. The Journal of experimental medicine. 2018 Academic Article GET IT
Times cited: 104
SETD2 - linking stem cell survival and transformation. Cell research. 2018 Comment GET IT
Times cited: 7
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular cell. 2018 Academic Article GET IT
Times cited: 13
Targeting mRNA Decapping in AML. Cancer cell. 2018 Comment GET IT
Times cited: 2
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA oncology. 2018 Academic Article GET IT
Times cited: 259
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery. 2018 Academic Article GET IT
Times cited: 86
Single-agent dabrafenib for BRAF^V600E-mutated histiocytosis. Haematologica. 2018 Academic Article GET IT
Times cited: 34
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature medicine. 2018 Academic Article GET IT
Times cited: 342
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leukemia research. 2018 Review GET IT
Times cited: 8
Editorial overview: Cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy. Current opinion in genetics & development. 2018 Editorial Article GET IT
Times cited: 3
The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. Molecular cell. 2018 Academic Article GET IT
Times cited: 186
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017 Academic Article GET IT
Times cited: 130
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017 Academic Article GET IT
Times cited: 489
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Academic Article GET IT
Times cited: 76
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric blood & cancer. 2017 Academic Article GET IT
Times cited: 15
Therapeutic targeting of RNA splicing in myelodysplasia. Seminars in hematology. 2017 Review GET IT
Times cited: 9
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017 Academic Article GET IT
Times cited: 97
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2017 Academic Article GET IT
Times cited: 51
Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017 Information Resource GET IT
Times cited: 157
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017 Academic Article GET IT
Times cited: 67
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017 Academic Article GET IT
Times cited: 88
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature communications. 2017 Academic Article GET IT
Times cited: 50
Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PloS one. 2017 Academic Article GET IT
Times cited: 25
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematology/oncology clinics of North America. 2017 Information Resource GET IT
Times cited: 18
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 Academic Article GET IT
Times cited: 121
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF^V600E in human cancers. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 28
Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. International journal of hematology. 2017 Information Resource GET IT
Times cited: 12
Modeling CBL activating mutations in vivo. Blood. 2017 Article GET IT
The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood advances. 2017 Academic Article GET IT
Times cited: 145
Histiocytoses: emerging neoplasia behind inflammation. The Lancet. Oncology. 2017 Information Resource GET IT
Times cited: 110
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell metabolism. 2017 Academic Article GET IT
Times cited: 103
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016 Academic Article GET IT
Times cited: 49
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature medicine. 2016 Academic Article GET IT
Times cited: 182
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 25
Therapeutic targeting of splicing in cancer. Nature medicine. 2016 Information Resource GET IT
Times cited: 387
Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood. 2016 Article GET IT
Times cited: 24
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer cell. 2016 Academic Article GET IT
Times cited: 176
Emerging concepts of epigenetic dysregulation in hematological malignancies. Nature immunology. 2016 Information Resource GET IT
Times cited: 71
Histiocytic neoplasms in the era of personalized genomic medicine. Current opinion in hematology. 2016 Information Resource GET IT
Times cited: 34
ASXL1 plays an important role in erythropoiesis. Scientific reports. 2016 Academic Article GET IT
Times cited: 35
Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British journal of haematology. 2016 Academic Article GET IT
Times cited: 26
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. Cancer cell. 2016 Academic Article GET IT
Times cited: 114
RNA splicing factors as oncoproteins and tumour suppressors. Nature reviews. Cancer. 2016 Information Resource GET IT
Times cited: 462
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature medicine. 2016 Article GET IT
Times cited: 7
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2016 Information Resource GET IT
Times cited: 5
Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice. Stem cell reports. 2016 Academic Article GET IT
Times cited: 16
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature medicine. 2016 Academic Article GET IT
Times cited: 267
Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes & development. 2016 Information Resource GET IT
Times cited: 84
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016 Academic Article GET IT
Times cited: 178
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Academic Article GET IT
Times cited: 230
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 Information Resource GET IT
Times cited: 951
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature communications. 2016 Academic Article GET IT
Times cited: 25
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Academic Article GET IT
Times cited: 107
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia. 2015 Academic Article GET IT
Times cited: 55
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. eLife. 2015 Academic Article GET IT
Times cited: 115
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature medicine. 2015 Academic Article GET IT
Times cited: 124
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2015 Academic Article GET IT
Times cited: 362
Loss of BAP1 function leads to EZH2-dependent transformation. Nature medicine. 2015 Academic Article GET IT
Times cited: 272
BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015 Academic Article GET IT
Times cited: 417
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 264
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell. 2015 Academic Article GET IT
Times cited: 341
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia. 2015 Article GET IT
Times cited: 54
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular cell. 2015 Academic Article GET IT
Times cited: 115
Hairy cell leukemia: update and current therapeutic approach. Current opinion in hematology. 2015 Information Resource GET IT
Times cited: 7
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
Times cited: 14
Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015 Academic Article GET IT
Times cited: 75
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia & lymphoma. 2015 Article GET IT
Times cited: 13
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer cell. 2015 Academic Article GET IT
Times cited: 424
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 153
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015 Article GET IT
Times cited: 46
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 2015 Academic Article GET IT
Times cited: 46
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer discovery. 2015 Academic Article GET IT
Times cited: 230
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell reports. 2014 Academic Article GET IT
Times cited: 218
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 225
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia & lymphoma. 2014 Information Resource GET IT
Times cited: 4
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer discovery. 2014 Academic Article GET IT
Times cited: 112
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia. 2014 Academic Article GET IT
Times cited: 63
BRAF-mutant hematopoietic malignancies. Oncotarget. 2014 Editorial Article GET IT
Times cited: 3
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014 Academic Article GET IT
Times cited: 188
Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochemical and biophysical research communications. 2014 Information Resource GET IT
Times cited: 27
Femoral bone marrow aspiration in live mice. Journal of visualized experiments : JoVE. 2014 Academic Article GET IT
Times cited: 14
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014 Academic Article GET IT
Times cited: 104
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 47
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 101
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica. 2014 Editorial Article GET IT
Times cited: 5
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 Academic Article GET IT
Times cited: 331
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes & development. 2014 Academic Article GET IT
Times cited: 67
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia & lymphoma. 2014 Information Resource GET IT
Times cited: 22
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica. 2014 Editorial Article GET IT
Times cited: 35
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 265
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. The Journal of clinical investigation. 2013 Academic Article GET IT
Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013 Article GET IT
Times cited: 47
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Academic Article GET IT
Times cited: 99
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Academic Article GET IT
Times cited: 174
Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Academic Article GET IT
Times cited: 139
Importance of genetics in the clinical management of chronic myelomonocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Editorial Article GET IT
Times cited: 9
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013 Academic Article GET IT
Times cited: 649
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013 Information Resource GET IT
Times cited: 212
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013 Academic Article GET IT
Times cited: 166
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Academic Article GET IT
Times cited: 124
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer cell. 2013 Academic Article GET IT
Times cited: 100
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nature medicine. 2013 Academic Article GET IT
Times cited: 187
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 130
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013 Academic Article GET IT
Times cited: 99
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 42
Focus on the epigenome in the myeloproliferative neoplasms. Hematology. American Society of Hematology. Education Program. 2013 Information Resource GET IT
Times cited: 10
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 138
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2012 Academic Article GET IT
Times cited: 56
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia research. 2012 Academic Article GET IT
Times cited: 30
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia. 2012 Information Resource GET IT
Times cited: 61
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European urology. 2012 Academic Article GET IT
Times cited: 176
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature genetics. 2012 Academic Article GET IT
Times cited: 643
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. British journal of cancer. 2012 Academic Article GET IT
Times cited: 93
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Academic Article GET IT
Times cited: 297
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematology/oncology clinics of North America. 2012 Information Resource GET IT
Times cited: 24
The role of mutations in epigenetic regulators in myeloid malignancies. Nature reviews. Cancer. 2012 Information Resource GET IT
Times cited: 515
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell. 2012 Academic Article GET IT
Times cited: 474
Refining the prognostic importance of the diversity of FLT3 internal tandem duplications. Leukemia & lymphoma. 2012 Article GET IT
Times cited: 1
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (New York, N.Y.). 2012 Academic Article GET IT
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 392
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Academic Article GET IT
Times cited: 82
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia & lymphoma. 2012 Article GET IT
Times cited: 19
Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. Hematology (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 6
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 Academic Article GET IT
Times cited: 183
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1562
Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Current hematologic malignancy reports. 2012 Information Resource GET IT
Times cited: 7
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Academic Article GET IT
Times cited: 1548
Interpreting new molecular genetics in myelodysplastic syndromes. Hematology. American Society of Hematology. Education Program. 2012 Information Resource GET IT
Times cited: 28
Clinical implications of novel mutations in epigenetic modifiers in AML. Hematology/oncology clinics of North America. 2011 Information Resource GET IT
Times cited: 37
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2011 Academic Article GET IT
Times cited: 68
FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples. Leukemia research. 2011 Editorial Article GET IT
Times cited: 1
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood. 2011 Academic Article GET IT
Times cited: 76
TET family proteins and their role in stem cell differentiation and transformation. Cell stem cell. 2011 Information Resource GET IT
Times cited: 199
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2011 Academic Article GET IT
Times cited: 32
Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 1281
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell. 2011 Academic Article GET IT
Times cited: 1034
Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011 Academic Article GET IT
Times cited: 36
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 Academic Article GET IT
Times cited: 316
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of biological chemistry. 2011 Academic Article GET IT
Times cited: 39
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer cell. 2011 Academic Article GET IT
Times cited: 202
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica. 2010 Article GET IT
Times cited: 19
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010 Academic Article GET IT
Times cited: 2183
PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2010 Academic Article GET IT
Times cited: 129
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 97
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer cell. 2010 Academic Article GET IT
Times cited: 233
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. The Journal of clinical investigation. 2010 Academic Article GET IT
Times cited: 153
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010 Article GET IT
Times cited: 67
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood. 2010 Academic Article GET IT
Times cited: 42
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010 Academic Article GET IT
Times cited: 267
Metabolism and the leukemic stem cell. The Journal of experimental medicine. 2010 Article GET IT
Times cited: 65
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell. 2010 Academic Article GET IT
Times cited: 1634
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010 Academic Article GET IT
Times cited: 67
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer research. 2010 Academic Article GET IT
Times cited: 262
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Academic Article GET IT
Times cited: 594
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009 Article GET IT
Times cited: 225
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 Academic Article GET IT
Times cited: 207
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 Academic Article GET IT
Times cited: 350
Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annual review of medicine. 2009 Information Resource GET IT
Times cited: 74
Functional evaluation of the grafted wall with porcine-derived small intestinal submucosa (SIS) to a stomach defect in rats. Surgery. 2007 Academic Article GET IT
Times cited: 16
Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006 Academic Article GET IT
Times cited: 252
Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006 Information Resource GET IT
Times cited: 124
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Molecular cancer therapeutics. 2006 Academic Article GET IT
Times cited: 38
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 44
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. The Journal of surgical research. 2005 Academic Article GET IT
Times cited: 19
In-transit melanoma: the role of alkylating-agent resistance in regional therapy. Journal of the American College of Surgeons. 2004 Academic Article GET IT
Times cited: 20
The role of hyperthermia in regional alkylating agent chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 27
Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery. 2004 Academic Article GET IT
Times cited: 26
Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cellular immunology. 2003 Academic Article GET IT

more ...

less ...

Background

education and training

M.D., Duke University School of Medicine 2004
B.Sc., Duke University 2000

Contact

full name

Omar Abdel-wahab

primary email

abdelwao@mskcc.org

VIVO Weill Cornell Medical College

Omar Abdel-wahab Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email